Cheng Yang

Cheng Yang

Auto-generated profile, based on publicly available information

Cheng Yang

Department of General Surgery 2, Central Hospital of Jinzhou City, Jinzhou, 121000, People's Republic of China

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2018 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
HLHongdan Li
Hongdan Li
CYCheng Yang
Cheng Yang
YSYijie Shi
Yijie Shi
LZLiang Zhao
Liang Zhao
Sorafenib is an effective clinical drug in therapy of hepatocellular carcinoma, having led to improved prognosis in hepatocellular carcinoma patients. However acquired resistance is still being encountered. So, it is urgently to develop alternative strategies to overcome drug resistance. Exosomes can be modified with a variety of molecules, thereby acting as a vehicle for the delivery of therapeutic agents. The GRP78 is overexpressed in Sorafenib resistant cancer cells compared to Sorafenib sensitive cancer cells and thus is able to act as a target for therapy of hepatocellular carcinoma. In this study, we modified BM-MSCs to express the exosomal siGRP78. And we show that siGRP78 modified exosomes combined with Sorafenib is able to target GRP78 in hepatocellular carcinoma cells and inhibit the growth and invasion of the cancer cells in vitro. Further, siGRP78 modified exosomes combined with Sorafenib also inhibit the growth and metastasis of the cancer cells in vivo. siGRP78 modified exosomes could sensitize Sorafenib resistant cancer cells to Sorafenib and reverse the drug resistance.

28 August 2013 in Molecular and Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
YWYi Wang
Yi Wang
YZY. X. Zhang
Y. X. Zhang
CKC. Z. Kong
C. Z. Kong
ZZZ. Zhang
Z. Zhang
YZY. Y. Zhu
Y. Y. Zhu